Skip to main content
. Author manuscript; available in PMC: 2020 Jun 15.
Published in final edited form as: Eur J Pharmacol. 2019 Apr 2;853:264–274. doi: 10.1016/j.ejphar.2019.03.052

Fig. 2. Effect of MTX on disease incidence and activity in the CIA mouse model.

Fig. 2

Disease incidence and activity were compared amongst control mice and mice undergoing the CIA protocol treated with weekly subcutaneous MTX at doses of 0, 2, 10, 20, or 50 mg/kg. Groups were compared based on the incidence of arthritis (A), disease activity (B), paw volume (C), and change in weight from baseline (D). Parameters were measured over the 54-day experimental period and the resulting mean±S.E.M. for each experimental group is presented.